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D. S. Wishart9, C. Andres Lacueva10,11, M. Garcia-Aloy10,11, H. Verhagen12,13, E. J. M. Feskens8 and G. Praticò1,2Abstract
Biomarkers of food intake (BFIs) are a promising tool for limiting misclassification in nutrition research where more
subjective dietary assessment instruments are used. They may also be used to assess compliance to dietary
guidelines or to a dietary intervention. Biomarkers therefore hold promise for direct and objective measurement of
food intake. However, the number of comprehensively validated biomarkers of food intake is limited to just a few.
Many new candidate biomarkers emerge from metabolic profiling studies and from advances in food chemistry.
Furthermore, candidate food intake biomarkers may also be identified based on extensive literature reviews such as
described in the guidelines for Biomarker of Food Intake Reviews (BFIRev). To systematically and critically assess the
validity of candidate biomarkers of food intake, it is necessary to outline and streamline an optimal and reproducible
validation process. A consensus-based procedure was used to provide and evaluate a set of the most important criteria
for systematic validation of BFIs. As a result, a validation procedure was developed including eight criteria, plausibility,
dose-response, time-response, robustness, reliability, stability, analytical performance, and inter-laboratory reproducibility.
The validation has a dual purpose: (1) to estimate the current level of validation of candidate biomarkers of food intake
based on an objective and systematic approach and (2) to pinpoint which additional studies are needed to provide full
validation of each candidate biomarker of food intake. This position paper on biomarker of food intake validation outlines
the second step of the BFIRev procedure but may also be used as such for validation of new candidate biomarkers
identified, e.g., in food metabolomic studies.
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Quantitative assessment of food intake is normally done
by the use of questionnaires, diaries, or interviews [1, 2].
These instruments are error-prone due to their subject-
ive nature [3]. The use of qualitative biomarkers to as-
sess recent food intake could be a qualification tool to
improve the value of current instruments for food intake
assessment. Further development of such biomarkers of
food intake to improve their use for quantitative assess-
ment of recent or more long-term food intake could be
a long-term goal in this field. In a recent paper, we have
suggested a flexible classification scheme for biomarkers* Correspondence: ldra@nexs.ku.dk
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(http://creativecommons.org/publicdomain/zeused in nutrition-related health research [4]. According to
this scheme, the biomarker classification is determined by
the intended use of the biomarker measurement. An im-
portant additional issue relates to biomarker validation.
Such validation will also depend on the purpose of using
the biomarker, i.e., on how the measurement may be inter-
preted. The development of a validation scheme would
therefore be necessary for each of the different biomarker
classes. Within the FoodBAll consortium (www.foodmeta-
bolome.org), the class of biomarkers of food intake (BFIs)
is the main focus area. A large number of candidate BFIs
are currently being observed in food metabolomic studies,
and others are found by extensive literature reviews such
as those following the BFIRev guidelines [5]. There are
also intervention studies covering a range of foods
performed in the FoodBAll project to discover newle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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biomarkers may be found for a large number of foods.
However, they must be validated to assure that they accur-
ately represent the level of intake of the food considered,
that the sample type and time of sampling is appropriate
for the intended use, and that the analytical method is
valid according to current standards.
Validation of a BFI is not only a matter of analytical
validity measured according to standards [6] but also a
matter of biological (nutritional) validity, i.e., what it
represents in terms of intake of a specific food under the
conditions of the study. Clearly, this will depend on fac-
tors such as variability of the content of biomarker pre-
cursors in foods and of their metabolism and kinetics in
individuals. Therefore, validation criteria must include
also biological aspects of the biomarker [7]. It is also im-
portant that the validity of a BFI is reconsidered for the
intended purpose whenever it is applied. Some efforts
have been made previously to evaluate biomarkers for
food or dietary intake in nutrition studies. For instance,
de Vries et al. proposed criteria to assess the meaningful-
ness of surrogate markers and pointed out that no clear
criteria could be set up for dietary intake markers, diet-
ary exposure markers, and nutritional status markers
due to the lack of established validation criteria [8]; Scal-
bert et al. suggested a grading system for BFIs to indicate
their level of validation. This approach introduces the
concept of stepwise improvement of validity, e.g., by the
use of a score or a set of criteria [9]. Several authors
have pointed out that a number of factors such as kin-
etic variables, factors related to sampling and storage,
and factors related to the variability of food composition
are important determinants of measurement error be-
yond simple analytical error [10–14]. However, there is
no systematic method established to validate BFIs. Here,
we propose a validation scheme for this particular group
of biomarkers. For newly discovered candidate BFIs, the
suggested validation criteria incorporate analytical and
biological aspects into a common system using eight
aspects of validation to allow partial or full validation.
Our purpose was to review the current stage of BFI
validation and to suggest appropriate steps for asses-
sing the validity of candidate BFIs. By applying this
validation scheme, researchers could obtain the infor-
mation needed to make good use of the BFIs and an
overview of the additional studies needed for the de-
velopment of the BFIs. To our knowledge, this is the
first comprehensive scheme developed for this area.
The resulting validation criteria and methodology
have been tested using Allium intake biomarkers as
an example and will subsequently be applied on can-
didate BFIs for all major foods or food groups. These
reviews will be published in this thematic issue of
Genes & Nutrition.Methods
In order to identify papers dealing with the validation of
BFIs, we carried out an extensive literature search fol-
lowing the BFIRev methodology proposed previously [4].
Briefly, searches were carried out in three databases
(PubMed, Scopus, and ISI Web of Knowledge) in No-
vember 2016. In PubMed, the search terms were (nutri-
tion*[Title/Abstract]) AND (biomarker*[Title] OR
marker*[Title]) AND (validation*[Title/Abstract] OR
validity*[Title/Abstract] OR validate*[Title/Abstract] OR
assessment*[Title/Abstract]) NOT (animal OR rat OR
mouse OR mice OR pig) NOT (disease*[Title] OR risk*[-
Title] OR inflammat*[Title/Abstract] OR patient*[Title]).
To avoid all the studies concerned with a single bio-
marker while keeping studies on validation in general,
we avoided using nutrient* or food* in the search strat-
egy. The fields used for the other two databases were
[Article Title/Abstract/Keywords] for Scopus and
[Topic] for ISI Web of Science to replace [Title/Ab-
stract] for PubMed. The search was limited to papers in
English language and with no restriction applied for the
publication dates. The review papers discussing the de-
velopment and application of biomarkers in the nutri-
tion field were selected in the process outlined in Fig. 1.
The first draft scheme of validation criteria was based
on criteria proposed in the review papers found by this
literature search. This list was revised by three rounds of
commenting by co-authors as well as feedback from pre-
sentations at international conferences.
Results
The literature search provided a range of factors to be
considered for the validation and application of bio-
markers in general or for BFIs in particular. These were
sub-grouped to provide eight separate characteristics
that may together comprise biomarker validity for BFIs
(Table 1). There is no intended hierarchy in the order.
A validation assessment system (questions 1–8) was
developed based on these characteristics. Validation can
be assessed for each candidate biomarker by evaluating
the current evidence related to each of the characteris-
tics proposed, thereby answering the related question.
Possible answers are Y (yes, the criterion is fulfilled for
at least some use of the biomarker), N (the criterion has
been investigated but it was not fulfilled), or U (the cri-
terion has not been investigated or data is not available).
Following the commenting rounds, the eight aspects of
validation remained although some of them are clearly
complex and may therefore only be answered positively
under certain conditions and these conditions must
therefore be stated. The validation questions and their
sub-criteria for answering “yes” are shown in Table 2.
The first five criteria are related to the biological valid-
ity and applicability in nutrition research; the remaining
Fig. 1 Flow diagram of search for papers on criteria for biomarker validation in nutrition field
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Many of these aspects may depend on the intended ap-
plication of the BFI, and the validity cannot therefore be
answered unambiguously in all cases. The criteria should
be seen as representative of the most important aspects
of the validation to be considered in the systematic
evaluation of each BFI. The conditions under which the
BFI is valid must therefore be added to qualify the valid-
ation. In their most simple form, the validation criteria
would translate into the questions added in the table.
Assessment of validity should consequently be possible
to perform in a reliable and documented manner using
these questions. For Y and N answers, the conditions
under which the validity has been assessed may be stated
as a comment. For instance, trimethylamine oxide
(TMAO) may be a valid short-term biomarker for intake
of cold-water fish from the sea when measured in urine
samples [15]. However, contents of TMAO may be lower
in some other fish making the marker unreliable for cer-
tain geographical areas [16].
The validation criteria may also be seen as criteria for
prioritization of further work on biomarker validation.
Whenever a question is answered by “N” or “U,” there is
a need for an additional work to provide the lacking
information. However, a conditional “Y” would also indi-
cate that further work may be needed. This should help
to identify the most promising BFIs and to plan any val-
idation work still needed in order to fully validate them.
The system is not geared towards scoring of validitysince each criterion may have different weight in differ-
ent applications of a biomarker. So validity may be suffi-
cient without eight Ys for some use of a biomarker. For
instance, the short-term kinetics would normally be ir-
relevant for biomarkers to be measured in hair samples
where only multiple-dose kinetics is of importance.
Discussion
Based on literature review and a consensus procedure, we
divided aspects of biological (nutritional) and analytical
validity into eight criteria. The underlying aspects of each
criterion may include several potential sources of unin-
tended variability in food intake assessments using the BFI
in question. While a similar procedure has been suggested
previously [9], this is to our knowledge the first attempt to
comprehensively and systematically develop a validation
procedure for BFIs. When applying this validation proced-
ure, it is important to be specific about the intended use.
This could be assessment of intake of a specific food or
the whole food group. For instance, biofluid measure-
ments of caffeine may be seen as a BFI for the food group
of caffeinated foods and drinks while being less useful for
any specific drink such as coffee. It may also be reasonable
to include aspects of variability such as that caused by
metabolism. Caffeine measurement would reveal recent
intake of caffeine-containing products, but it is extensively
metabolized. Caffeine metabolism has variable kinetics
based on common variation in genetics and lifestyle
factors [17, 18], and this might cause limitations for
Table 1 Factors to be considered for the validation and application of biomarkers suggested in previous literature
Characteristic Factors to be considered for the validation and application of biomarkers References
1. Plausibility • Biomarkers should be specific to the food (having the ability to distinguish the food or food
component of interest from other foods or food components).
• There should be a food chemistry or experimentally based explanation for why the food intake
should increase the biomarker, e.g., the biomarker should be a metabolite of a food component.
[71–81]
2. Dose-response • Evaluation of the dose-response relationship should be performed to assess the suitability
of the biomarker over a range of intakes.
• Limit of detection should be evaluated to provide the information about how responsive (sensitive)
the biomarker is.
• Baseline habitual level needs to be established.
• Bioavailability of (the precursor of) the biomarker should be evaluated to provide the information
about its sensitivity to intake.
• Detailed information about saturation effects of the biomarker should be known.
[9, 10, 12, 13, 71,
73–88]
3. Time-response • The half-life of the biomarker should be evaluated to specify the degree to which a
biomarker reflects exposure, e.g., days, weeks, months or years.
• Kinetics (comprises “formation, distribution, metabolism and excretion”) should be known to
make choices, such as on sampling time and matrices.
• Timing of measurement in relation to bioavailability and bioefficacy must be considered.
• Temporal relation of the biomarker with dietary intake should be considered to provide
information for choosing types of specimen.
• Repeated measures of the biomarker over time should be evaluated to provide insight
into the reproducibility of biomarker concentrations, and thus, the likelihood that the
biomarker is a stable estimate of long-term intake.
[9, 10, 12, 71, 74, 76,
77, 79, 82, 85–87, 89]
4. Robustness • Suitability of the biomarker in a free-living population should be investigated using a (controlled)
habitual diet to provide information such as its interactions with other foods and its applicability
to a certain group of population.
• The biomarker should be validated in a controlled dietary intervention studies as well as in
cross-sectional studies.
• Validation of the biomarker in different subjects and study settings is needed.
• Information such as interactions with other food components and influence of food matrix
should be excluded or known to be manageable.
[12, 76, 80, 85]
5. Reliability • Comparison of the biomarker and a gold standard or reference method that provides
a good measure of the true exposure is necessary.
• Biomarkers identified using samples from cohort studies should ideally be combined
with intervention studies to demonstrate their direct relationships with intake.
• Comparison between the biomarker and an appropriate dietary assessment method
should be performed.
• A biomarker should be confirmed in accordance with other biomarkers for the same
food or foods.
• Validation of a biomarker can be attempted by measuring it in animals fed different
nutrient intake under tightly controlled conditions.
[9, 11, 13, 71, 72, 74,
75, 77, 84, 87, 90]
6. Stability • Suitable protocols for sample collection, processing, and storage are needed to
keep the sample quality for several years.
• Trials should be carried out to determine whether analytes undergo decomposition
during storage.
[76]
7. Analytical performance • Precision, accuracy, and detection limits of the method should be evaluated.
• Comparison against validated methodology or references or references materials
is needed.
• The calculation of inter- and intra-batch variation should be performed.
• Statistical quality control procedures (coefficient of variance, standard deviation and
inaccuracy limits for data) should be established.
[10–13, 71–74, 76,
82, 84, 91]
8. Reproducibility • There is the need to develop and use accurate and validated analytical methods to
adequately compare the data obtained in different laboratories.
[12, 71, 78]
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the sum of major caffeine metabolites in a 24-h urine
might perform better as a quantitative BFI for this class of
foods [19].
Candidate BFIs have often been based mainly on infor-
mation from food chemistry pointing to special com-
pounds found only in specific foods or food groups. The
relatively well-studied alkylresorcinols BFIs of (wholegrain) wheat and rye intake are a good example of this
[20, 21]. More recently, BFIs are frequently suggested
from metabolomic studies. For instance, proline betaine
was observed in several early studies and further con-
firmed as a BFI for citrus by Heinzmann et al. [22]. The
metabolic profiling studies can have highly variable de-
signs, e.g., experimental meal studies, dietary intervention
studies, or cross-sectional studies [9, 23]. The study in
Table 2 Eight groups of validity criteria for biomarkers of food intake
Validation criterion Validation questions and their sub-criteria for answering “yes”
1. Plausibility Q: Is the marker compound plausible as a specific BFI for the food or food group (chemical/biological plausibility)?
((The BFI is likely to be a metabolite or process-related derivative of a compound known to occur in the food or food group)
OR (the BFI has been identified as a putative biomarker for the food/food group) OR (the compound was identified as a
putative biomarker in a metabolomics investigation))
AND (variability of (parent) compound within food or food group (if known) is limited)
AND ((the level of the (parent) compound in other foods is comparatively low) OR (presence only in other foods not
commonly consumed))
2. Dose-response Q: Is there a dose-response relationship at relevant intake levels of the targeted food (quantitative aspect)?
(The dose-response relationship of the BFI has been established using several intake levels (in a meal study) OR
(in different meal studies where the results were comparable) OR (in cross-sectional study or longitudinal observational
studies))
AND (the background level of the BFI is 0 or low)
Information about the limits for common background levels and saturation kinetics of the BFI should be provided as
a comment
3. Time-response Q: Is the biomarker kinetics described adequately to make a wise choice of sample type, frequency and time window
(time-response)?
a. (The single-meal time-response relationship of the BFI has been described for a defined sample type and time
window in a meal study) OR
b. (The kinetics of the BFI after repeated intakes has been described for a defined sample type in a meal study) OR
(accumulation of the BFI in certain sample types has been observed)
Information about ADME and enzyme induction, inhibition, or altered excretion in the metabolism of the BFI or its
precursor could be provided as a comment.
4. Robustness Q: Has the marker been shown to be robust after intake of complex meals reflecting dietary habits of the targeted population
(robustness)?
((The BFI has been measured and shown to be robust after intake of complex meals (in intervention studies) OR
(in observational studies))
AND ((There is no confounding food observed) OR (The level of the BFI from the confounding food is low) OR
(The confounding foods are not commonly consumed))
5. Reliability Q: Has the marker been shown to compare well with other markers or questionnaire data for the same food/food group
(reliability)?
(The BFI has been compared well (with other biomarkers for the same food or food group) OR (with dietary assessment
instruments) OR (with data in studies with highly controlled setting and supervised intake)
6. Stability Q: Is the marker chemically and biologically stable during biospecimen collection and storage, making measurements
reliable and feasible (stability)?
(The BFI is chemically and biologically stable during biospecimen collection, processing and storage) OR (The BFI is
not stable but suitable protocol has been established to achieve the stabilisation of the BFI)
7. Analytical performance Q: Are analytical variability (CV%), accuracy, sensitivity and specificity known as adequate for at least one reported analytical
method (analytical performance)?
(The protocol of the method has been well described and could be repeated)
AND (The method has been compared with validated method or references)
AND (The analytical variability (CV%), accuracy, sensitivity and specificity have been described)
8. Reproducibility Q: Has the analysis been successfully reproduced in another laboratory (reproducibility)?
(The analysis with the same method has been performed in at least 2 different laboratories)
AND (The measurements of the BFI obtained from different laboratories are comparable)
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some information related to one or more criteria of valid-
ation. This depends on the study design, e.g., plausibility
based on food chemistry studies, kinetics based on post-
prandial concentrations in plasma or urine from meal
studies, quantitative aspect based on different levels of
exposures in dietary interventions, or robustness based on
findings from a cross-sectional or other observational
setting.
Each of the eight criteria defined above is further dis-
cussed below along with suggestions on the studies and
sample methods most suitable for validation. Since none
of the validation questions in Table 2 may be answered
without influence of some of the aspects covered by oneor more other criteria, the discussion of each criterion
also includes some of the interrelations with the others.
1. Plausibility. The amount of analytical information
on foods and food groups is extensive and
increasing rapidly with the use of metabolomics in
food chemistry. Available knowledge on food
composition and food compound metabolism is
more and more integrated into online databases
(FooDB, Phenol-Explorer, PhytoHub, etc.), which
facilitate the identification of biomarkers specific for
individual foods. A candidate BFI may therefore be
suggested and evaluated based on the food chemistry
literature as already exemplified in the case of the
Dragsted et al. Genes & Nutrition  (2018) 13:14 Page 6 of 14alkylresorcinols. An important aspect here is the
variability of contents within the food source, e.g., as
a result of different varieties, and growth conditions.
High and unpredictable variability may reduce the
usefulness of a food compound as a BFI; this may for
instance be the case for feed and pasture-derived
compounds in dairy products [24]. Another possible
origin of a candidate BFI could be the food processing
such as fermentation or heating. For instance, during
the cooking of meat, heterocyclic aromatic amines
could be formed from creatinine, creatine, and amino
acids at high temperature, which may be a biomarker
of intensively cooked meat intake [25]. As an example
of more complex markers based on food production,
four different beer metabolites have been proposed as
a combined marker of beer intake, two of them
reflecting beer raw materials (hops and barley) and
the other two reflecting the production processes
(malting and fermentation), respectively [26]. If a
candidate biomarker is highly specific (only minor
interference is expected from other food sources), or
unique for the food or food group in question, it is
likely to have good plausibility. Interference from
other sources may be expected to be low because
other potential sources have either low content or a
very low level of consumption in the population
considered. For newly suggested BFIs, this check
based on current knowledge from food chemistry in
combination with knowledge on possible host
metabolism may represent the first step to evaluate
chemical and biological plausibility. Plausibility is an
essential criterion for any BFI but not sufficient, as a
very specific compound may for example be too
variable in contents in the food, too unstable in the
food or in body fluids, or be unreliable due to a high
inter-individual variation in ADME; some of these
aspects are covered below.
2. Dose-response after a single exposure. This
validation criterion may be satisfied if short-term or
long-term dose-response relationship in humans
has been clearly established for the candidate
biomarker. For compounds with short half-lives,
this may be accomplished with meal studies using
several intake levels of a single food having a known
content of the BFI or its precursor. Short-term
dose-response information may also be achieved by
analyzing cross-sectional or longitudinal data where
24 h records of food intake is available together
with appropriate biological samples. BFIs with
longer half-lives may not show postprandial dose-
response kinetics at all and still be good biomarkers
for assessing longer term ingestion of a food. Lipid-
soluble compounds such as lycopene are examples
of this [27]. For compounds like carotenoids, whichare transferred into deeper compartments and only
slowly released it is not possible to assess their
short-term kinetics in blood after a single exposure
[28]. Postprandial dose-response is therefore
obviously not always needed for validation and must
therefore often be answered together with a
comment explaining the possible reason for the lack
of dose-response. The presence of postprandial
dose-response indicates that the marker has
relatively fast kinetics into the body fluid sampled
and that background levels are low compared to the
change following food intake. This would happen
for relatively water soluble, uniquely food-derived
compounds that diffuse or are transported into the
blood, that are not removed by the liver in the first
pass, that are not the subject of multiple pathways
of degradation, and that are excreted at a similar
rate in most subjects. A typical example of such a
BFI is proline betaine, which is almost inert to
human metabolism while reflecting recent exposure
to citrus fruit products [22]. For the measurement
of urinary 1-methylhistidine, representing meat
intake, postprandial dose-response is visible in
highly controlled studies but the background level
is too high so that lower meat intakes cannot be
detected [29–31]. Excretion of 3-methylhistidine is
therefore preferred, but this compound is not found
in all meats and seems to be a better marker for
chicken than for others [31]. Actually, the situation
for 1-methylhistidine is not unusual and many
biomarkers may have background levels due to low
levels in some other foods and/or to endogenous
formation. Even proline betaine is present at 100–
1000 times lower levels in other fruits and
vegetables, so a low background level may be seen
even without citrus exposure [22]. Whenever
possible, the limits for common background levels
may therefore be added in a comment to this criter-
ion to describe levels that do not indicate exposure
to the target food. Any indication of saturation kin-
etics at higher intake levels may be another
phenomenon that may be relevant to note in BFI
short-term dose-response studies although
saturation phenomena in nutrition are currently
best known from nutrient intake biomarkers (NIBs)
such as ascorbate.
3. a. Time-response after a single exposure. This
question relates to the optimal time window for
measurement of a BFI. This depends on the uptake
or elimination half-life of the BFI determined after a
single exposure to the food. The importance of this
criterion may again depend on the intended
application; it is important in order to point out
whether there is evidence to use the BFI for a
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causing variability in postprandial dose-response
(variable contents in foods, variable ADME) would
also apply here. Qualifying statements relating to
food and individual variability may consequently be
needed in addition to Y or N. Absorption that leads
to measurable levels of the BFI in blood over an
extended number of hours would mean that blood
samples may be useful for food intake assessment
within that specified time interval after food intake.
BFIs with fast metabolism or excretion would
narrow the useful time window for blood samples.
Proline betaine showing fast absorption and
excretion may be measured in blood in only a short
time interval, whereas collection of urine over a
time span of a few hours or more would recover
almost all proline betaine ingested in that time
interval. Urine samples would therefore represent
recent intakes before or during biospecimen
collection for these BFIs. This is important because
repeated urine sampling over a time period may be
used to represent the frequency of intake of the
target food in the study period or in the habitual
diet of the study subjects [25]. The urine sampling
plan (frequency and duration of collection) will
therefore determine the ability of a study to provide
food intake information for BFIs with shorter half-
lives. Late absorption and excretion occurs for BFIs
that depend on release by the gut microbiota. An
example of such markers is the urolithins which are
formed by certain microbes during degradation of
ellagic acid from berries and nuts [32, 33]. These
markers are only excreted after 24–36 h following
intake of ellagitannins and may peak at 48–72 h
[34, 35]. For BFIs with complex absorption kinetics
and/or a very long elimination half-life after absorp-
tion such as the carotenoids, the single-dose
exposure kinetics may be of less relevance because
background levels are usually high. Repeated-dose
kinetics (criterion 3b) is more important for these
BFIs
b. Time-response after multiple exposures. The
time-response after single exposures may need add-
itional considerations related to repeated intakes of
the same food or food group. The time-response
after multiple exposures includes phenomena such
as accumulation in hair or blood plasma or cumula-
tive increases in excretion. This information is of
importance to select the best possible sample type
and timing of the sample collection for the assess-
ment of habitual intake. Accumulation of the bio-
marker in blood, hair, or nails is affected by
repeated exposures to some foods, and therefore, it
could reflect the current habitual intakes. Forinstance, the measurement of alcoholic beverage in-
take by ethyl glucuronide in hair may be suitable
for estimating habitual intakes since it builds up in
hair after exposure to multiple doses in the longer
term [36]. This would not be the case for urine or
blood where the presence of the marker reflects
only recent intake. However, further
characterization of this marker for different kinds of
hair, for subjects with different polymorphisms of
ethanol metabolism, etc. may still be needed in
order to fully validate this marker for quantitative
longer term intake assessment [37]. Most BFIs have
not been studied in hair and more studies are
needed to evaluate the usefulness of hair or nail
clippings for BFIs currently measured mainly in
blood or urine. For the medium-range or slowly ex-
creted food-derived compounds such as lycopene,
quercetin, or lipids, plasma levels may build up. For
instance, after consumption of tomato, the plasma
level of lycopene needs 3–4 days to return to base-
line, which makes it a good biomarker for habitual
tomato intake in most cases where the frequency of
tomato ingestion is more than once a week [24].
For quercetin with an excretion half-life of around
16–20 h, this would still allow plasma kinetics to be
studied after a single meal in most cases, whereas
plasma levels of C22:6 fatty acids from seafood may
not change appreciably after a single seafood meal
in habitual consumers of fatty fish but only as a
consequence of repeated exposures making blood
samples potentially useful for measuring habitual in-
takes [38, 39]. The accumulation as a consequence
of different dietary levels should therefore be evalu-
ated for this BFI. Enzyme induction, inhibition, or
altered excretion may affect kinetics of elimination
after repeated exposures. Foods such as coffee, gar-
lic, and cabbages contain inducers of phase 1 or
phase 2 metabolism, including diterpenes, disul-
phides, indoles, and isothiocyanates. These phenom-
ena are not well studied in humans while animal
studies indicate efficacy of these compounds in en-
zyme induction [40]. When induction may be ex-
pected, it should be evaluated whether it might
affect the use of the BFI, in particular whether this
effect may dominate over other sources of variabil-
ity. Other commonly ingested foods might also in-
fluence the ADME of a candidate BFI so that its
kinetics may depend on the food matrix or even cu-
linary culture as shortly discussed below under cri-
terion 4.4. Robustness in studies with complex diets. It is
important to evaluate the robustness of the BFI
when it is intended for use in observational studies
with complex meals or diets. Many candidate BFIs
Dragsted et al. Genes & Nutrition  (2018) 13:14 Page 8 of 14have been suggested based on a limited number of
intervention studies with highly controlled diets or
on food chemistry knowledge. However, these data
may not be sufficient to identify all other possible
dietary sources of the BFI. For instance, limonene
metabolites may be observed as good candidate
markers of citrus intake in a controlled intervention
study. Since limonene is also very abundant in
citrus flavored foods (sweets, cakes, etc.), the use of
it as a BFI would potentially lead to wrong
conclusions counting unhealthy foods as fruit [41].
Whereas criterion 1, plausibility, is based on food
chemistry literature, robustness is evaluated based
on actual proof of the uniqueness of the BFI under
conditions where multiple other foods are
consumed at the same time. Such studies are
typically cross-sectional or prospective studies
where intake is monitored by food diaries or dietary
recalls. For example, robustness of proline betaine
was confirmed as it appeared as a biomarker
predicting citrus intake versus no intake
independently of study design; this included a
cross-sectional study where citrus fruit intake was
monitored by 24 h records in a free-living
population, a fully controlled meal study with citrus,
and a 4-week intervention with orange juice [42]. In
a few cases, robustness may also be judged based on
multiple complex meals containing one of the foods
of interest [43]. Applicability of a BFI in populations
with different food cultures or production systems
may require an examination of the BFI robustness
in each population. For instance, δ13C has been
suggested as a BFI of added sugar refined from C4
plants such as corn, sugar cane, and sorghum. It
works well in a population whose major source of
sugar is C4 plants such as subjects in Mexico,
Canada, and USA. However, for Europeans or
Japanese who largely rely on sugar beet, a C3 plant,
the use of δ13C may underestimate the intake of
added sugar [44, 45]. Another aspect of
robustness is the influence of other foods on
the metabolism and kinetics of the BFI. This
aspect is not well studied but may be indicated
from some observations. For instance, the
disruption of fat micelle formation in the gut
by foods rich in plant sterols leading to reduced
cholesterol uptake [46] may also affect other
lipid-soluble compounds, but so far, this has only
been shown to affect carotenoids [47]. So in a
comparison of subjects with differences in habitual
plant sterol intake, carotenoids may in theory not
estimate intake of plant foods in a balanced way.
However, direct evidence for quantitative importance
is still lacking.5. Reliability based on other markers of intake for the
food in question. Reliability is traditionally the
comparison of a new biomarker against the current
best (gold) standard methodology [13]. This
validation of a BFI should ideally be done in a
highly controlled setting with supervised intake so
that the exact amount of the food consumed is
monitored for each volunteer in the study. In such
a study, direct comparison by plots such as Bland-
Altman and/or Passing-Bablok can be performed
for exact validation and outlier detection [48, 49].
Alternatively, the new BFI is validated against a
previously validated “gold standard” for intake
assessment of the food in question, but such a
method is only rarely available for BFIs. So the
current best practice may be the use of dietary
assessment instruments. Validated questionnaire
data, food records, or diaries may be available to
judge the reliability of the marker. This is not ideal
since it implies validation of a potentially more
objective and precise instrument by less precise and
subjective information. Depending on the precision
of the dietary instrument, the quality of the
validation by this criterion will vary. Food diaries
and 24-h dietary recalls covering the day of blood
or urine collections for BFI measurement should be
preferred over food frequency questionnaires for
reliability assessments. A useful resource is the
Exposome-Explorer database in which over 8000
correlation values between biomarker levels and
intake of a large diversity of foods have been curated
for a large number of BFIs [50]. In some cases, several
new candidate markers are found simultaneously by
metabolomics [51]. Such new BFIs representing the
same food may be validated for reliability against each
other in a separate analysis to compare their capacity
to accurately predict food intake [52]. This latter
strategy is not without pitfalls as exemplified above
with proline betaine and limonene metabolites, both
markers of citrus intake but with vastly different
robustness in mixed meal studies [41]. This strategy
for evaluating reliability should therefore be
interpreted with care, preferably using data from
different study designs; observational evidence of
reliability may for instance be confirmed in a
controlled trial or evidence from controlled studies
may find confirmation from a cross-sectional setting
where several different intake levels can provide
information about concordance between the
candidate BFIs. Simultaneous use of information
from dietary assessment instruments in such studies
as described above would help to assure that the
markers also agree reasonably with subjective food
intake data.
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related to best practices for sample collection and
storage. Compound structure, sample collection,
storage and handling, and sample pre-processing
should be considered when evaluating the stability
aspect for an intended use of a candidate biomarker.
Many metabolites have been found to be quite
stable over time under conditions of low-
temperature storage [53]. However, both
temperature and environment are important
determinants. It is generally accepted that storage at
temperatures of − 20 °C or higher is suboptimal and
leads to oxidative degradation. However, systematic
studies of storage stability at − 80 °C over a longer
time period are very few beyond a few years [54]
and have not covered many food compounds, so
the practice of sample storage for 5–10 years used
for many cohorts and experimental studies is not
well documented. Storage stability in these cases
may be evaluated by comparing the distribution of
concentrations measured in a set of stored and
fresh samples of comparable origin or by repeated
analyses of a set of QC samples, stored in
multiplicates. Storage at even lower temperature
and under a nitrogen atmosphere is probably ideal
and even enzyme activities seem to be in the
normal range after more than 10 years of storage
under such conditions [55, 56]. Inherent compound
stability and potential for enzymatic breakdown
during sampling is another issue that must be
carefully considered under this validation criterion.
For instance, highly oxidizable compounds such as
beer humulones may degrade during storage of the
beverage as well as during collection of urine sam-
ples voided into an oxygen-containing collection jar.
Such compounds may only serve as BFIs when both
the parent compound and the products are known
and measured [26]. Other potential degradation
pathways include pH instability and metabolism by
enzymes or cells present in the preparation. Special
collection conditions may be needed for stabilizing
certain BFIs, e.g., special tubes for ascorbate and
glucose stabilization as well as urine collection at
pH below 2 for anthocyanins [57–59].
7. Analytical performance of the BFI measurement.
Reliable chemical analysis is of central importance
for any BFI. Several analytical quality aspects exist,
including precision, accuracy, and intra-batch and
inter-batch variability; however, these are
concatenated here into a single validation criterion
to assess whether qualitative or quantitative analysis
of the BFI is feasible. Comments to Y answers are
therefore mandatory for this criterion in order to
qualify the statement by providing details of theanalytical performance of the BFI analysis method.
Few BFIs have been thoroughly validated in targeted
analytical procedures by modern standards of
analytical quality and what is sufficient may depend
heavily on the intended use, e.g., qualitative or
quantitative use. A candidate biomarker found by
metabolomics must obviously have been measured at
different levels in a body fluid under the conditions of
the untargeted analysis applied. This indicates
potential for qualitative (or so-called semi-
quantitative) use and reflects the minimal
requirement for Y with the comment, “qualitative
analysis only.” In studies where the BFI additionally
reflected known graded differences in exposures, the
development of the method applied into a targeted,
quantitative analysis may be judged as feasible under
similar experimental conditions. This would reflect
the minimal evidence to indicate potential for
development of a quantitative analytical method for
the BFI, and this information may be added as a
comment but quantitative use would still be
uncertain until an analytically validated method has
been developed. The adequacy of an intended
analytical method should therefore be carefully
considered before application of a BFI with this kind
of minimal evidence for analytical performance. In
most instances, a thorough analytical method
validation for a biomarker is not made until a
dedicated targeted method is being developed. This
question should therefore be answered positively only
with an accompanying comment on its potential for
use in qualitative and quantitative applications. For
the former, a sufficient limit of detection may be
adequate. For the latter, a targeted method which has
been analytically validated according to current
recommendations by analytical chemistry journals or
societies [60–62] is needed to assure uncompromised
use of the BFI. For full validation, it is necessary to
use an isotope-labelled standard for the BFI as
reference in every sample, but such standards are not
available for most compounds. However, new
methods for derivatization with labelled agents may
help solve this issue, depending on the compound
structure [63–65]. For instance, free short-chain fatty
acids may be measured quantitatively using both a la-
belled and an unlabelled agent for derivatization of
carboxylic acids [66].
8. Reproducibility across laboratories. Measurement of
a BFI should give the same result when analyzed in
different laboratories. Repeatability is indicated
when the same analysis of the marker has been
reproduced in at least two different laboratories but
should eventually be evaluated by inter-laboratory
comparison tests. Such tests apply the final, targeted
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distributed in a blinded fashion to the participating
laboratories. Inter-laboratory comparisons are often
used for assessment of laboratory performance [67],
and this must also be considered if the procedure is
used for validation; if one of the laboratories does not
follow the analytical procedure well, the outcome
may erroneously indicate that the BFI is not
repeatable across laboratories. It is therefore
preferable that several laboratories contribute. Inter-
laboratory comparisons may even be performed with
metabolomic methodology, i.e., before a fully
validated analytical procedure has been developed
[68, 69]; however, a carefully standardized
metabolomics procedure should then be used by all
participating laboratories to avoid misinterpretation
of biomarker validity.
Variable levels of a BFI at a fixed food intake could come
from differences in metabolism due to the age, sex, smok-
ing, medicine; from influence of other dietary factors or
microbiota; from factors affecting stability of the marker;
or from variable contents of the biomarker precursor in
the food. Variability is also seen within an individual due
to several of these factors. Biomarker variability is an im-
portant issue across most criteria but has not been consid-
ered a criterion as such because many aspects of variation
can be controlled technically by careful sampling, analyt-
ical procedures, and statistical handling. The un-
controllable factors are the individual differences in me-
tabolism, variable contents in the food, and food matrix
effects. When they are large compared to the variation in
intakes of the food in question, the biomarker may not be
useful and this will be observed in careful dose-response
and time-response studies (criteria 2 and 3) and in studies
of robustness (criterion 4). For instance, the sulphate con-
jugate of 4-ethyl-5-methylamino-pyrocatechol was ob-
served having an apparent dose-response relationship
with beetroot intake in a parallel intervention study [43].Table 3 Criteria need to be fulfilled for different uses of BFIs




3a Time-response (single dose) √





8 ReproducibilityThe dose-response curve clearly indicated considerable
variability; such variability may be due to variation in the
presence of the parent betalain in the beetroot dishes con-
sumed or to differences between individuals in betalain
metabolism. This could be caused by large inter-individual
variations in its endogenous metabolism (hydrolysis and
conjugation) and in metabolism by the microbiota. Exten-
sive metabolism or degradation could therefore constitute
a drawback for the use of this BFI considering that its vari-
ation is high compared with the variations in intake. For
microbial metabolites in general, their presence may de-
pend on the presence of a certain metabolic functionality
of the microbiota. As a consequence, they may show
major variation between individuals, making them less
useful as BFIs, as demonstrated for the urolithins [70]. Fi-
nally, apparent variation in sample concentrations at a cer-
tain food intake may be caused by the use of food diaries
as reference measurement since volunteers may not cor-
rectly note the ingested amount of the food in question.
Controlled dietary studies are therefore needed to investi-
gate variability. Most of these sources of variability are not
only affecting the validation process but also affect the in-
terpretation of validated food intake biomarkers. Careful
and repeated sampling and/or use of markers with longer
half-lives tend to reduce the influence of variable contents
in the food or intake levels. Variable metabolism is more
difficult to control by technical means and could render a
BFI useful only at the group or population level.
By these eight validation questions, the current status
of biological/analytical validation, including reliability
and robustness of a biomarker, can be assessed. For the
purpose of reviews on BFIs including their validation ac-
cording to the current criteria, the number of questions
answered “Y” may be used as a score; however, since the
questions may not be equally important for all BFIs, the
application of such a score to rank BFIs according to
validity may be misleading. More rigid criteria for when
to answer Y or N to each of the criteria could be helpful;
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stricter criteria. The current validation approach is
therefore based on explanatory comments to supplement
the evaluation of Y or N. Although the validation is
intended to provide a more authoritative guidance re-
garding the potential of a candidate biomarker, validity
of a BFI will depend on the intended application and
must always be considered by the user. The explanatory
comments are therefore important for the end user to
judge a given application.
When the validation criteria are applied for use of BFIs
as qualitative markers, the scheme may be followed less
stringently (Table 3). For instance, dose-response charac-
teristics and analytical validation do not need to be docu-
mented in detail for qualitative BFIs since an all-or-none
response is all that would be required. The presence of
ethyl glucuronide in a blood sample, for instance, would
clearly indicate that an alcoholic beverage has been
ingested within the last 24 h. This measurement would
suffice for assessment of compliance even if the analytical
procedure is not done with internal standards. For this
biomarker, the use of an internal standard would provide
an accurate concentration and for a 24 h urine sample also
the amount of beverage ingested recently. The number of
criteria met as such may not be very informative, except
for a rough estimate of how much further validation may
be needed. For example, a biomarker having five Ys but
with N for questions 1, 4, and 5 may not be useful at all.
However, in case the lacking evidence is for questions 1
(parent food compound still unknown), 3b, and 8, it would
seem quite reliable even for quantitative use since only
inter-laboratory comparisons may additionally be needed.
So as already underlined repeatedly, the user must still
take care to check that any of the validation criteria may
apply for the intended use and appreciate that overall val-
idation can only be made for a defined application.
Conclusions
This paper outlines a simple validation system for candi-
date BFIs identified from a literature search, from meta-
bolomic studies, or from food chemistry. The validation
criteria were identified from the literature and further
grouped by the authors. The validation system has the
advantage of pointing out the specific areas where a BFI
is sufficiently validated while also highlighting those as-
pects where additional studies would be needed in order
to provide improved validation. An important strength
of this approach is therefore that it provides a stepwise
strategy to improve the validity of existing BFIs as well
as a test strategy for new candidate BFIs emerging from
metabolomic studies, literature review, or from food
chemistry. The validation system for BFIs proposed here
includes aspects of plausibility, precision, stability, sin-
gle or repeated intake kinetics, reliability, robustness,repeatability, comparability, and analytical perform-
ance. These criteria include all aspects of validation
suggested in previous reviews on this topic. Although
some of the criteria may simply be answered Y or N,
commenting on specific conditions for the judgement
of validity of a BFI may often be needed in order to
pinpoint limitations on its use.
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